Document is current

Article History

Received: 10 January 2022

Accepted: 20 August 2022

First Online: 6 September 2022

Declarations

:

: All authors affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

: Not required.

: Dr Fay Cafferty reports receipt of research grants for the Add-Aspirin trial from Cancer Research UK and the National Institute of Health Research, as well as study drug provision from Bayer Pharmaceuticals.Dr Claire Snowdon, Professor Judith Bliss, Professor Emma Hall and Dr Sarah Kernaghan reports grants from Cancer Research UK, grants and non-financial support from AstraZeneca, grants and non-financial support from Puma Biotechnology, during the conduct of the study.Dr Joshua Savage reports grants from Cancer Research UK, grants from The Brain Tumour Charity, during the conduct of the study; personal fees from Eli Lilly, outside the submitted work.Dr Philip Pallmann: Health & Care Research Wales, Cancer Research UK support my institution (Centre for Trials Research) with core infrastructure funding which is used to fund time for otherwise unfunded research projects, including work on this paper.Professor Timothy Maughan declares funds related to FOCUS4 from EME programme of MRC, Cancer Research UK and AstraZeneca.Dr Nicholas Turner has received advisory board honoraria from Astra Zeneca, Bristol-Myers Squibb, Lilly, Merck Sharpe and Dohme, Novartis, Pfizer, Roche/Genentech, GlaxoSmithKline, Zentalis pharmaceuticals, Repare therapeutics, Arvinas and research funding from Astra Zeneca, BioRad, Pfizer, Roche/Genentech, Merck Sharpe and Dohme, Guardant Health, Invitae, Inivata, Personalis, Natera.Professor Christina Yap reports grants from Cancer Research UK, grants from Cancer Research UK, personal fees from Celgene, personal fees from Faron Pharmaceuticals Ltd, grants and other from AstraZeneca, during the conduct of the study.Professor Mehanna is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, or the Department of Health and Social Care.Professor Andrew Tutt declares AstraZeneca Grant to The Institute of Cancer Research for an Externally Sponsored Collaborative Research Trial PHOENIX.Professor Mahesh Parmar received research funding to the institution from Astellas, Clovis, Janssen, & Pfizer.Professor Matthew Sydes received research funding to the institution from Astellas, Clovis, Janssen, Novartis, Pfizer, Sanofi-Aventis; received speaker fees from Lilly Oncology & Janssen; independent member of data monitoring committees.All other authors have no conflicts of interests to declare for this work.